Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05982509
Other study ID # G2204
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 11, 2022
Est. completion date July 27, 2023

Study information

Verified date August 2023
Source CGBio Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical study is to evaluate the effect on skin regeneration after applying EasyDew MD Regen Cream containing Neopep-S, a regeneration factor, to patients who have undergone picosure picosure laser skin treatment as needed.


Description:

This clinical study is a researcher-led randomized control group comparative clinical study that is conducted prospectively for one month after applying medical devices for clinical research. The subjects are those who have undergone a picosure laser procedure for therapeutic purposes on the skin tissue of the face or body, and a screening test is conducted after the subject (and/or legal representative) agrees in writing to participate in the clinical study. The screening test results are evaluated, and subjects who meet the selection criteria and do not meet the exclusion criteria are registered in clinical research. Participating subjects are randomly assigned to the control group and the study group using a random number table at a 5:5 ratio. - Control group: 10 people without treatment - Study Group: 10 People Applying EasyDu Regen MD Cream Clinical study subjects are randomly assigned to control and study groups. In the case of the study group, the Easy Dew Regen MD cream provided through prescription is applied twice a day (morning and evening) to the skin of the area where the picosure laser treatment has been performed and absorbed well. The control group is the non-chalant group. However, general moisturizers that were used at home rather than medical devices for one month after the procedure can be used, and they are applied twice a day (morning and evening) to the skin of the area where the laser treatment has been performed and absorbed well. One month of clinical research medical device application will be observed, and subjects will regularly visit the research institution to evaluate its validity and safety during screening visits (Visit1), treatment (Visit2), 2 weeks after treatment (Visit3), and 1 month after treatment (Visit3) You will receive it.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 27, 2023
Est. primary completion date July 27, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria: - Those aged 19 to 65 who have undergone picosure laser treatment on facial and body skin tissues - Decided to participate in this clinical study and signed a written informed consent the subject Exclusion Criteria: - Subjects with uncontrolled diabetes - Subjects with uncontrolled hypertension and cardiovascular disease - Subjects with hemorrhagic diseases such as hemophilia - Immunosuppressants, corticosteroids, cytotoxic agents, and anticoagulants can affect the results Subjects who are or are scheduled to receive medication for an extended period of time - Acute or chronic skin disease causes stage progression or active bacteria in the application area Who has a virus infection - When the researcher's judgment determines that participation in the study is inappropriate (e.g. keloid constitution)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EasyDew Regen MD Cream
For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.

Locations

Country Name City State
Korea, Republic of Ajou University Hospital Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
Eun-ji Kim

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transepidermal water loss Transcutaneous water loss (TEWL) measured Before, immediately after treatment, and one month after application of the medical device Transcutaneous water loss (TEWL) measured Before, immediately after treatment, and one month after application
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03238053 - Laser Treatment of Genito-urinary Syndrome in Women N/A